Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corcept TherapeuticsFRA:HTD -0.39%85 Shiller PE Ratio is 120.47 as of Aug. 20, 2026, which is 74% above its 10-year median of 69.29. GuruFocus rates FRA:HTD with a GF Score™ of 85/100 and a GF Value™ of €59.75 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 172 Biotechnology companies, Corcept Therapeutics ranks worse than 87.79% on this metric.
The historical rank and industry rank for Corcept Therapeutics's Shiller PE Ratio or its related term are showing as below:
FRA:HTD'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 32.11 Med: 69.29 Max: 679.5
Current: 122.43
During the past years, Corcept Therapeutics's highest Shiller PE Ratio was 679.50. The lowest was 32.11. And the median was 69.29.
FRA:HTD's Shiller PE Ratio is ranked worse than 87.79% of 172
companies
in the Biotechnology industry
Industry Median: 33.135
vs FRA:HTD: 122.43
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Corcept Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was €0.312. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is €0.85 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Corcept Therapeutics (FRA:HTD) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Corcept Therapeutics Shiller PE Ratio Related Terms
Corcept Therapeutics Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HTD vs APGE, KRYS, NUVL: Shiller PE Ratio Comparison
For the Biotechnology subindustry, Corcept Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics Shiller PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Corcept Therapeutics (FRA:HTD) has a Shiller PE Ratio of 120.47 as of Aug. 20, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Corcept Therapeutics and its competitors. This is 74% above median its historical median of 69.29. Over the past decade, Corcept Therapeutics' Shiller PE Ratio has ranged from 32.11 to 679.50. According to the industry distribution chart, Corcept Therapeutics ranks #151 out of 172 companies in the Biotechnology industry, placing it in the top 87.8%.
Is Corcept Therapeutics' Shiller PE Ratio too high?
Corcept Therapeutics' current Shiller PE Ratio of 120.47 is 74% above median its 10-year median of 69.29. Over the past 10 years, this metric has ranged from a low of 32.11 to a high of 679.50. The Biotechnology industry median Shiller PE Ratio is 33.14. Corcept Therapeutics' value of 120.47 is 263.6% above this industry median. Based on the distribution chart, Corcept Therapeutics ranks #151 out of 172 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Shiller PE Ratio compare to APGE and KRYS?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #151 out of 172 companies for Shiller PE Ratio. This places Corcept Therapeutics in the lower half of its industry. The industry median Shiller PE Ratio is 33.14. Corcept Therapeutics' value of 120.47 is 263.6% above this benchmark. Historically, Corcept Therapeutics' own Shiller PE Ratio has ranged from 32.11 to 679.50 over the past decade. While the company's 10-year median is 69.29 vs. the industry median of 33.14, Corcept Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Biotechnology company?
The median Shiller PE Ratio among Biotechnology companies is 33.14, based on 172 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corcept Therapeutics's current Shiller PE Ratio of 120.47 is 263.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Corcept Therapeutics and its competitors. For the Biotechnology industry, the median Shiller PE Ratio is 33.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corcept Therapeutics's current Shiller PE Ratio is 120.47, which is 74% above median its own 10-year median of 69.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (FRA:HTD) is currently considered Significantly Overvalued. The stock's GF Value™ is €59.75, compared to a current price of €102.40 — trading 71.4% above its estimated fair value. The current Shiller PE Ratio is 120.47, which is 74% above median its 10-year median of 69.29 and 263.6% above the Biotechnology industry median of 33.14. Corcept Therapeutics' overall GF Score™ is 85/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Corcept Therapeutics (FRA:HTD), the current Shiller PE Ratio is 120.47 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (FRA:HTD) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of €102.40 is trading 71.4% above its estimated GF Value™ of €59.75.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:HTD:
Shiller PE Ratio: 120.47 (74% above median its 10-year median of 69.29)
GF Value™: €59.75 vs. price of €102.40 (71.4% above fair value)
Industry Position: 263.6% above the Biotechnology median (#151 of 172)
No single metric tells the full story. See the FRA:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score
Get the complete analysis for FRA:HTD
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HTD has been successfully added to your 
